579 related items for PubMed ID: 18978521
1. Comparison of pharmacokinetics of mycophenolic acid and its glucuronide between patients with lupus nephritis and with kidney transplantation.
Mino Y, Naito T, Matsushita T, Otsuka A, Ushiyama T, Ozono S, Hishida A, Kagawa Y, Kawakami J.
Ther Drug Monit; 2008 Dec; 30(6):656-61. PubMed ID: 18978521
[Abstract] [Full Text] [Related]
2. Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant.
Pawinski T, Durlik M, Szlaska I, Urbanowicz A, Majchrnak J, Gralak B.
J Clin Pharm Ther; 2006 Feb; 31(1):27-34. PubMed ID: 16476117
[Abstract] [Full Text] [Related]
3. Pharmacokinetics of mycophenolic acid and its phenolic-glucuronide and ACYl glucuronide metabolites in stable thoracic transplant recipients.
Ting LS, Partovi N, Levy RD, Riggs KW, Ensom MH.
Ther Drug Monit; 2008 Jun; 30(3):282-91. PubMed ID: 18520599
[Abstract] [Full Text] [Related]
4. Cyclosporine alters correlation between free and total mycophenolic acid in kidney transplant recipients in the initial phase.
Mino Y, Naito T, Otsuka A, Takayama T, Ozono S, Kagawa Y, Kawakami J.
J Clin Pharm Ther; 2011 Apr; 36(2):217-24. PubMed ID: 21366651
[Abstract] [Full Text] [Related]
5. Pharmacokinetics of mycophenolic acid and its glucuronidated metabolites in stable lung transplant recipients.
Ting LS, Partovi N, Levy RD, Riggs KW, Ensom MH.
Ann Pharmacother; 2006 Sep; 40(9):1509-16. PubMed ID: 16882870
[Abstract] [Full Text] [Related]
6. Cyclosporine concentration-dependent increase in concentration ratio of mycophenolic acid acyl and phenol glucuronides to mycophenolic acid in stable kidney transplant recipients.
Mino Y, Naito T, Otsuka A, Ushiyama T, Ozono S, Kagawa Y, Kawakami J.
Clin Biochem; 2009 May; 42(7-8):595-601. PubMed ID: 19100248
[Abstract] [Full Text] [Related]
7. Concentrations of mycophenolic acid and glucuronide metabolites under concomitant therapy with cyclosporine or tacrolimus.
Patel CG, Harmon M, Gohh RY, Akhlaghi F.
Ther Drug Monit; 2007 Feb; 29(1):87-95. PubMed ID: 17304155
[Abstract] [Full Text] [Related]
8. Impact of calcineurin inhibitors on urinary excretion of mycophenolic acid and its glucuronide in kidney transplant recipients.
Naito T, Mino Y, Otsuka A, Ushiyama T, Ito T, Ozono S, Kagawa Y, Kawakami J.
J Clin Pharmacol; 2009 Jun; 49(6):710-8. PubMed ID: 19451405
[Abstract] [Full Text] [Related]
9. Effects of calcineurin inhibitors on pharmacokinetics of mycophenolic acid and its glucuronide metabolite during the maintenance period following renal transplantation.
Naito T, Shinno K, Maeda T, Kagawa Y, Hashimoto H, Otsuka A, Takayama T, Ushiyama T, Suzuki K, Ozono S.
Biol Pharm Bull; 2006 Feb; 29(2):275-80. PubMed ID: 16462031
[Abstract] [Full Text] [Related]
10. Effect of t-tube clamping on the pharmacokinetics of mycophenolic acid in liver transplant patients on oral therapy of mycophenolate mofetil.
Jain AB, Hamad I, Zuckerman S, Zhang S, Warty VS, Fung JJ, Venkataramanan R.
Liver Transpl Surg; 1999 Mar; 5(2):101-6. PubMed ID: 10071348
[Abstract] [Full Text] [Related]
11. Influence of renal insufficiency on pharmacokinetics of ACYL-glucuronide metabolite of mycophenolic acid in renal transplant patients.
González-Roncero FM, Govantes MA, Chaves VC, Palomo PP, Serra MB.
Transplant Proc; 2007 Sep; 39(7):2176-8. PubMed ID: 17889129
[Abstract] [Full Text] [Related]
12. Evaluation of MPA and MPAG removal by continuous venovenous hemodiafiltration and continuous venovenous hemofiltration.
Cussonneau X, Bolon-Larger M, Prunet-Spano C, Bastien O, Boulieu R.
Ther Drug Monit; 2008 Feb; 30(1):100-2. PubMed ID: 18223470
[Abstract] [Full Text] [Related]
13. Comparison of pharmacokinetics of mycophenolic acid and its metabolites between living donor liver transplant recipients and deceased donor liver transplant recipients.
Shen B, Chen B, Zhang W, Mao H, Shen C, Deng X, Zhan X, Chen H.
Liver Transpl; 2009 Nov; 15(11):1473-80. PubMed ID: 19877254
[Abstract] [Full Text] [Related]
14. Pharmacokinetics of mycophenolic acid in kidney transplant patients receiving sirolimus versus cyclosporine.
El Haggan W, Ficheux M, Debruyne D, Rognant N, Lobbedez T, Allard C, Coquerel A, Ryckelynck JP, Hurault de Ligny B.
Transplant Proc; 2005 Mar; 37(2):864-6. PubMed ID: 15848558
[Abstract] [Full Text] [Related]
15. Pharmacokinetic role of protein binding of mycophenolic acid and its glucuronide metabolite in renal transplant recipients.
de Winter BC, van Gelder T, Sombogaard F, Shaw LM, van Hest RM, Mathot RA.
J Pharmacokinet Pharmacodyn; 2009 Dec; 36(6):541-64. PubMed ID: 19904584
[Abstract] [Full Text] [Related]
16. Pharmacokinetics of mycophenolic acid and its glucuronide metabolites in stable adult liver transplant recipients with renal dysfunction on a low-dose calcineurin inhibitor regimen and mycophenolate mofetil.
Beckebaum S, Armstrong VW, Cicinnati VR, Streit F, Klein CG, Gerken G, Paul A, Oellerich M.
Ther Drug Monit; 2009 Apr; 31(2):205-10. PubMed ID: 19307937
[Abstract] [Full Text] [Related]
17. Mycophenolic acid clinical pharmacokinetics influenced by a cyclosporine C2 based immunosuppressive regimen in renal allograft recipients.
Mandla R, Midtvedt K, Line PD, Hartmann A, Bergan S.
Transpl Int; 2006 Jan; 19(1):44-53. PubMed ID: 16359376
[Abstract] [Full Text] [Related]
18. AcylMPAG plasma concentrations and mycophenolic acid-related side effects in patients undergoing renal transplantation are not related to the UGT2B7-840G>A gene polymorphism.
van Agteren M, Armstrong VW, van Schaik RH, de Fijter H, Hartmann A, Zeier M, Budde K, Kuypers D, Pisarski P, Le Meur Y, van der Werf M, Mamelok RD, Oellerich M, van Gelder T.
Ther Drug Monit; 2008 Aug; 30(4):439-44. PubMed ID: 18641546
[Abstract] [Full Text] [Related]
19. Pharmacokinetics of enteric-coated mycophenolate sodium in stable pediatric renal transplant recipients.
Ettenger R, Bartosh S, Choi L, Zhu W, Niederberger W, Campestrini J, Bastien MC, Schmouder R.
Pediatr Transplant; 2005 Dec; 9(6):780-7. PubMed ID: 16269051
[Abstract] [Full Text] [Related]
20. The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients.
Kuypers DR, Naesens M, Vermeire S, Vanrenterghem Y.
Clin Pharmacol Ther; 2005 Oct; 78(4):351-61. PubMed ID: 16198654
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
